美沙拉嗪联合布地奈德治疗溃疡性结肠炎临床效果

刘开宇

（枣庄矿业集团东郊医院，山东 枣庄，277119）

浏览次数：117次 下载次数：380次

摘要：

目的 探讨美沙拉嗪联合布地奈德治疗溃疡性结肠炎的临床效果，为溃疡性结肠炎的临床治疗提供新思路。方法 选取 2013年4月至2015年2月我院收治的86例溃疡性结肠炎患者为研究对象，将其随机分为对照组和观察组，各43例。对照组患者采用口服美沙拉嗪联合地塞米松保留灌肠治疗，观察组患者采用口服美沙拉嗪联合布地奈德保留灌肠治疗。经过8周治疗后，通过结肠镜检查，比较两组患者的临床效果及不良反应发生情况。结果 观察组患者的总有效率为86.05%，对照组患者的总有效率为65.12%，观察组总有效率明显高于对照组（P<0.05）；观察组不良反应总发生率为18.60%，对照组不良反应总发生率为39.53%，观察组患者的不良反应总发生率明显低于对照组（P<0.05）。结论 美沙拉嗪联合布地奈德保留灌肠 治疗溃疡性结肠炎，临床效果显著，不良反应少，值得临床推广应用。

关键词：美沙拉嗪；布地奈德；溃疡性结肠炎

中图分类号：R574.62 文献标志码：A文章编号：2096-1413(2017)26-0040-02

Clinical effect of mesalazine combined with budesonide in the treatment of ulcerative colitis
LIU Kai-yu
(Eastern Suburb Hospital of Zaozhuang Mining Group, Zaozhuang 277119, China)

ABSTRACT: Objective To explore the clinical effect of mesalazine combined with budesonide in the treatment of ulcerative colitis, and provide new ideas for the clinical treatment of ulcerative colitis. Methods A total of 86 cases of patients with ulcerative colitis admitted in our hospital from April 2013 to February 2015 were selected as the study objects, all the patients were randomly divided into control group and observation group, with 43 cases in each group. The control group was treated with oral mesalazine combined with dexamethasone retention enema, and the observation group was given oral mesalazine combined with budesonide retention enema. After 8 weeks of treatment, the clinical effects and adverse reactions of the two groups were compared by colonoscopy. Results The total effective rate of the observation group was 86.05%, and that of the control group was 65.12%, the total effective rate of the observation group was higher than that of the control group (P<0.05). The total incidence rate of adverse reactions of the observation group was 18.60%, and that of the control group was 39.53%, the total incidence rate of adverse reactions of the observation group was lower than that of the control group (P<0.05). Conclusion Mesalazine combined with budesonide in the treatment of ulcerative colitis has significant clinical effect and less adverse reactions, which is worthy of clinical application and promotion.
KEYWORDS: mesalamine; budesonide; ulcerative colitis

参考文献：
[1] 江学良,权启镇,王志奎.溃疡性结肠炎的诊断、分型及疗效标准[J]. 世界华人消化杂志,2000,8(3):332-334.
[2] 谭悦,杨俊,郑长青.美沙拉嗪口服联合灌肠治疗溃疡性结肠炎的疗效评价[J].实用药物与临床,2012,15(6):344-346.
[3] 刘敏,董卫国,张吉翔,等.布地奈德和美沙拉嗪对活动期炎症性肠病疗效及安全性的Meta 分析[J].胃肠病学和肝病学杂志,2014,23(1):60-65.
[4] 中华医学会消化病学分会炎症性肠病协作组,欧阳钦,胡品津,等. 对我国炎症性肠病诊断治疗规范的共识意见(2007 年,济南)[J].中华消化杂志,2007,27(8):545-550.
[5] 江勇,吕宗舜,张志广,等.树突细胞、白介素-23与溃疡性结肠炎的关系[J].世界华人消化杂志,2015,23(5):834-838.
[6] 白文元,刘娜.布地奈德治疗炎性肠病的机制与疗效[J].临床药物治疗杂志,2011,9(2):37-40.
[7] 师永盛,霍丽娟,安丽婷.培菲康联合美沙拉嗪治疗轻中度溃疡性结肠炎的临床疗效观察[J].山西医科大学学报,2011,42(3):222-225.